Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07163013
Recruiting Not applicable

Digital Cognitive Behavioral Therapy for Chinese Adolescents With Depressive Symptoms（CADS-D )

NCT07163013 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Chongqing Medical University
Phase
Not applicable
Started
2025-05-12
Last updated
2026-01-27

Condition(s) studied

Depressive Symptom

Investigational drug(s) / intervention(s)

Digital cognitive behavioral therapy(DCBT)Regular mental health curriculum

Digital cognitive behavioral therapy(DCBT): Moca is a mobile application designed to deliver structural CBT for adolescents with mood problems. Moca provides six-twelve guided sessions with an estimated proceeding duration of 25-45min each, developed to be processed weekly. The content of each session includes the introduction of the core concepts and principles of CBT, psychological counseling dialogue, skill exercises, and homework. Content presentation forms include text, animation, audio, comics, etc. At the end of each module, the participants will be asked to submit homework that will ask them to apply their learned skills to nursing or daily life situations that they personally perceive as stressful. Participants can review the completed sessions and record their mood status during the intervention period.

Regular mental health curriculum: The content of regular mental health curriculum includes mental health education lecture. Few lectures address the knowledge and skills involved in CBT in such education lecture.

Study summary

CADS-D aimes to evaluate the effectiveness and feasibility of a newly DCBT program for Chinese adolescents with depressive symptoms.

Eligibility

Sex
ALL
Min age
12 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 12 to 18 years; 2. Scored 28 or higher on the children's depression rating scale-revised (CDRS-R); 3. Have the ability to read and write in Chinese; 4. Participant and at least one of their guardians provided written consent; 5. Have access to mobile phone and internet. Exclusion Criteria: 1. The researchers assessed that the adolescent's depressive symptoms were too severe to participate to CADS-D; 2. Scored 5 or higher on item 13 (suicidal ideation) on CDRS-R; 3. Participants who met diagnosis of other mental disorder except depression; 4. Severe physical illnesses or other physical disabilities that prevented the use of DCBT; 5. Within the past three months or currently undergoing any antidepressant treatment, including medication therapy, psychotherapy, and physical therapy; 6. Unavailability to follow up months after intervention.

Primary outcome measure(s)

  • Change in CDRS-R (Children's Depression Rating Scale) scores from baseline — Baseline of intervention period, 6 weeks, and 3 months follow-up (18 weeks)
    Children's Depression Rating Scale is a 17 items observer-rated scale developed specifically for children and adolescents. Total scores range from 17-113, with higher scores indicating greater severity of depressive symptoms.

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Chongqing Medical University Chongqing China Recruiting

More First Affiliated Hospital of Chongqing Medical University trials in China

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer Recruiting
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST Recruiting
Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer Recruiting
Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study Recruiting
Metabolomics Predictors for Metabolic Disease Remission After Metabolic Syndrome Surgery. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07163013 on ClinicalTrials.gov ↗ ← All trials in China